These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22391783)

  • 1. Fragile X population carrier screening.
    Metcalfe SA; Archibald AD; Couns G
    Genet Med; 2012 Mar; 14(3):350; author reply 351. PubMed ID: 22391783
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanded carrier screening and the law of unintended consequences: from cystic fibrosis to fragile X.
    Grody WW
    Genet Med; 2011 Dec; 13(12):996-7. PubMed ID: 22134443
    [No Abstract]   [Full Text] [Related]  

  • 3. Cystic fibrosis and fragile X syndrome: the arguments for antenatal screening.
    Murray J; Cuckle H
    Comb Chem High Throughput Screen; 2001 May; 4(3):265-72. PubMed ID: 11375741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Making a (cautious) case for expanding reproductive genetic carrier screens: Australian researchers report success, and caveats, with a simultaneous panel of cystic fibrosis, fragile X syndrome, and spinal muscular atrophy.
    Am J Med Genet A; 2018 Mar; 176(3):510-512. PubMed ID: 29446568
    [No Abstract]   [Full Text] [Related]  

  • 5. Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests.
    Archibald AD; Smith MJ; Burgess T; Scarff KL; Elliott J; Hunt CE; McDonald Z; Barns-Jenkins C; Holt C; Sandoval K; Siva Kumar V; Ward L; Allen EC; Collis SV; Cowie S; Francis D; Delatycki MB; Yiu EM; Massie RJ; Pertile MD; du Sart D; Bruno D; Amor DJ
    Genet Med; 2018 Apr; 20(5):513-523. PubMed ID: 29261177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues.
    Bailey DB; Skinner D; Davis AM; Whitmarsh I; Powell C
    Pediatrics; 2008 Mar; 121(3):e693-704. PubMed ID: 18310190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "It's something I need to consider": decisions about carrier screening for fragile X syndrome in a population of non-pregnant women.
    Archibald AD; Jaques AM; Wake S; Collins VR; Cohen J; Metcalfe SA
    Am J Med Genet A; 2009 Dec; 149A(12):2731-8. PubMed ID: 19938084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis, genetics, and DNA technology.
    Nugent CE
    Curr Opin Obstet Gynecol; 1991 Apr; 3(2):235-41. PubMed ID: 1912355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "It's about having the choice": stakeholder perceptions of population-based genetic carrier screening for fragile X syndrome.
    Archibald AD; Hickerton CL; Jaques AM; Wake S; Cohen J; Metcalfe SA
    Am J Med Genet A; 2013 Jan; 161A(1):48-58. PubMed ID: 23239566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal genetic testing.
    Dolan SM
    Pediatr Ann; 2009 Aug; 38(8):426-30. PubMed ID: 19711880
    [No Abstract]   [Full Text] [Related]  

  • 11. Population-based carrier screening and prenatal diagnosis.
    Strom CM
    MLO Med Lab Obs; 2004 Aug; 36(8):12-7; quiz 20-1. PubMed ID: 15366363
    [No Abstract]   [Full Text] [Related]  

  • 12. Pediatricians' attitudes toward expanding newborn screening.
    Acharya K; Ackerman PD; Ross LF
    Pediatrics; 2005 Oct; 116(4):e476-84. PubMed ID: 16199673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis.
    Zhang L; Bao Y; Riaz M; Tiller J; Liew D; Zhuang X; Amor DJ; Huq A; Petelin L; Nelson M; James PA; Winship I; McNeil JJ; Lacaze P
    Genet Med; 2019 Sep; 21(9):1958-1968. PubMed ID: 30773532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for single gene genetic disease.
    Musci TJ
    Gynecol Obstet Invest; 2005; 60(1):19-26. PubMed ID: 15731563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of screening strategies for fragile X syndrome in the UK.
    Pembrey ME; Barnicoat AJ; Carmichael B; Bobrow M; Turner G
    Health Technol Assess; 2001; 5(7):1-95. PubMed ID: 11262423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.
    Watson MS; Cutting GR; Desnick RJ; Driscoll DA; Klinger K; Mennuti M; Palomaki GE; Popovich BW; Pratt VM; Rohlfs EM; Strom CM; Richards CS; Witt DR; Grody WW
    Genet Med; 2004; 6(5):387-91. PubMed ID: 15371902
    [No Abstract]   [Full Text] [Related]  

  • 17. FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States.
    Hantash FM; Goos DM; Crossley B; Anderson B; Zhang K; Sun W; Strom CM
    Genet Med; 2011 Jan; 13(1):39-45. PubMed ID: 21116185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying CFTR molecular genetics to facilitate the diagnosis of cystic fibrosis through screening.
    Bobadilla JL; Farrell MH; Farrell PM
    Adv Pediatr; 2002; 49():131-90. PubMed ID: 12214770
    [No Abstract]   [Full Text] [Related]  

  • 19. Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children.
    Hiraki S; Ormond KE; Kim K; Ross LF
    Am J Med Genet A; 2006 Nov; 140(21):2312-9. PubMed ID: 17036312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of population screening for fragile X syndrome.
    Hill MK; Archibald AD; Cohen J; Metcalfe SA
    Genet Med; 2010 Jul; 12(7):396-410. PubMed ID: 20548240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.